BioPharmSignal logoBioPharmSignal

Biotech News

MaxCyte Announces Planned CFO Transition in 2026

MaxCyte (MXCT)MaxCyteCompany update

Company initiates search for successor ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell

Related news

MXCTMaxCyte2026-08-19 12:05 EST

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

MXCTMaxCyte2026-07-21 12:05 EST

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

SGMOSangamo Therapeutics, Inc.2026-04-29 12:05 EST

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

View all latest news

MaxCyte

Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...

Recent company news

MXCTMaxCyte2026-08-19 12:05 EST

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

MXCTMaxCyte2026-08-12 20:05 EST

MaxCyte Reports Second Quarter 2026 Financial Results

MXCTMaxCyte2026-07-21 12:05 EST

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

MXCTMaxCyte2026-07-15 20:05 EST

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

MXCTMaxCyte2026-06-23 13:00 EST

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

Stock data

Close
1.38 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States